Category

Latest News
Published Date:2023-11-30 Original Link:https://www.onenessbio.com/en/news_detail252_1.htm No 1 Date of announcement 2023/11/30 Time of announcement 17:00:06 Subject Oneness announces the resolution of the Board of Directors on the Record Date of Capital Increase for the issuance of Restricted Employee Shares in 2023. To which item it meets paragraph 53 Date of events 2023/11/30 Statement Date of occurrence...
Read More
Published Date:2023-11-29 Original Link:https://www.onenessbio.com/en/news_detail251_1.htm No 1 Date of announcement 2023/11/29 Time of announcement 17:01:08 Subject An European patent titled “USE OF FLAVONOID COMPOUND IN PREPARATION OF COMPOSITION FOR HEALING WOUND” has been granted. To which item it meets paragraph 53 Date of events 2023/11/29 Statement Date of occurrence of the event:2023/11/29 Company name:ONENESS BIOTECH CO.,...
Read More
Published Date:2023-11-13 Original Link:https://www.onenessbio.com/en/news_detail365_1.htm Contact Us繁簡EN
Read More
Published Date:2023-11-10 Original Link:https://www.onenessbio.com/en/news_detail250_1.htm No 1 Date of announcement 2023/11/10 Time of announcement 17:20:22 Subject Oneness Biotech Co., Ltd. receives a Hong Kong patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101). To which item it meets paragraph 53 Date of events 2023/11/10 Statement 1.Date of occurrence of the event:2023/11/10...
Read More
Published Date:2023-11-09 Original Link:https://www.onenessbio.com/en/news_detail249_1.htm No 2 Date of announcement 2023/11/09 Time of announcement 20:54:04 Subject FESPIXON, the new drug in treatment of diabetic foot ulcers has been approved as Class 1.1 natural new drug by National Medical Products Administration (NMPA) in China. To which item it meets paragraph 10 Date of events 2023/11/09 Statement 1.Product:FESPIXON,...
Read More
Published Date:2023-11-09 Original Link:https://www.onenessbio.com/en/news_detail248_1.htm No 1 Date of announcement 2023/11/09 Time of announcement  16:52:05 Subject The Company’s 2023Q3 consolidated financial statements have been approved by the Board of Directors. To which item it meets paragraph 31 Date of events 2023/11/09 Statement 1. Date of the board of directors submitted or approved:2023/11/09 2. Date of the...
Read More
Published Date:2023-10-25 Original Link:https://www.onenessbio.com/en/news_detail247_1.htm No 1 Date of announcement 2023/10/25 Time of announcement  17:07:38 Subject Oneness has submitted medical device registration application of Bonvadis for wound care to the Thai Food and Drug Administration (Thai FDA) in Thailand. To which item it meets paragraph 10 Date of events 2023/10/25 Statement   1. Product:Bonvadis for wound...
Read More
Published Date:2023-10-04 Original Link:https://www.onenessbio.com/en/news_detail246_1.htm No 1 Date of announcement 2023/10/04 Time of announcement  17:16:08 Subject The board of directors of the Company approved removal of the noncompete clause for managers. To which item it meets paragraph 21 Date of events 2023/10/04 Statement Date of the board of directors resolution:2023/10/04 Name and title of the managerial...
Read More
Published Date:2023-10-03 Original Link:https://www.onenessbio.com/en/news_detail367_2.htm Contact Us繁簡EN
Read More
Published Date:2023-10-02 Original Link:https://www.onenessbio.com/en/news_detail245_2.htm No 1 Date of announcement 2023/10/02 Time of announcement  16:52:23 Subject The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD To which item it meets paragraph 12 Date of events 2023/10/03 Statement Date...
Read More
1 11 12 13 14 15 32